Improved survival in tumor-bearing SCID mice treated with interferon-γ-inducible protein 10 (IP-10/CXCL10)

Cancer Immunology, Immunotherapy

Volumn 50, Issue 10, 2001, Pages 533-538

  Arenberg, Douglas A ^a   White, Eric S ^a   Burdick, Marie D ^b   Strom, Scott R ^a   Strieter, Robert M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Chemokines; Cytokines; Tumor immunity

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER MORTALITY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINES, CXC; FEMALE; HUMANS; INTERFERON TYPE II; LUNG NEOPLASMS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0035668187     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-001-0231-9     Document Type: Article

References (28)

1. The CXC chemokine, monokine induced by interferon gamma (MIG), inhibits non-small cell lung cancer (NSCLC) tumor growth and metastasis
2. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases
3. The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model
4. Epidemiology and etiology of lung cancer
5. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance
6. Cancers of the lungs
7. Lung cancer
8. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture
9. Relation of vascular proliferation to tumor growth
10. Tumor angiogenesis
11. Tumor dormancy in vivo by prevention of neovascularization
12. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
13. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
14. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12
15. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
16. Monoclonal antibodies against heparin binding growth factor II/basic fibroblast growth factor that block its biological activity: Invalidity of the antibodies for tumor angiogenesis
17. Angiostatin: A novel angiogenesis inhibitor that mediates suppression of metastases by a Lewis lung carcinoma
18. Angiostatin induces and sustains dormancy of human primary tumors in mice
19. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
20. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
21. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity
22. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
23. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo
24. Inhibition of IL-8 attenuates angiogenesis in bronchogenic carcinoma
25. Excessive production of TGF-ß can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth
26. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells
27. Chemokines: A new classification system and their role in immunity